This inventor holds 1 USPTO granted patent and 3 published patent applications. Top assignees: Aperisys, Inc., The General Hospital Corporation. Active years: 2023.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:

Years Active: 2023
Title: The Innovative Journey of Stephen J McCormack
Introduction: Stephen J McCormack, based in Las Vegas, NV, is a notable inventor whose contributions to the field of biotechnology have made a significant impact. His work revolves around the development of antigen-binding fusion proteins, showcasing a blend of scientific expertise and innovative thinking.
Latest Patents: McCormack holds a patent for "Antigen-binding fusion proteins with modified HSP70 domains." This invention encompasses fusion proteins that integrate an antigen-binding domain with a modified heat shock 70 protein. The significance of this patent lies in its potential applications, which include inducing immune responses to specific antigens and treating diseases associated with such antigens.
Career Highlights: Throughout his professional journey, Stephen J McCormack has made substantial contributions while working at prominent organizations. He has held positions at Aperisys, Inc. and The General Hospital Corporation, where he utilized his skills and knowledge to further advance research and development in the biotechnology realm.
Collaborations: In the course of his career, McCormack has collaborated with other talented professionals, including Timothy Alan Brauns and Mark C Poznansky. These partnerships have played a crucial role in enhancing the efficacy of his research endeavors and inventions.
Conclusion: Stephen J McCormack’s innovative spirit and dedication to the field of biotechnology underscore the importance of collaboration and creativity in scientific advancement. His patent on antigen-binding fusion proteins is a testament to the strides made in this industry, potentially leading to groundbreaking therapeutic options for diseases.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile